Etubics

Welcome to Etubics

Etubics Corporation is a Seattle based biopharmaceutical company developing targeted immunotherapies and vaccine products for a wide range of resilient diseases. Etubics patent-protected technology has been proven to be safer, more efficient and more effective than current vectored vaccines and gene delivery platforms.

We specialize in developing innovative immunotherapies and vaccines utilizing our exclusive next-generation viral vector gene delivery technology and our patented manufacturing cell line, together the Etubics Platform.

The Etubics Platform delivers a long lasting “active” immune response against diseases and induces both cell mediated immunity and antibody. The Etubics Platform provides the following capabilities:

  • Utilization of boosting
  • Enhanced CMI response
  • No unwanted viral replication in the body
  • Treatment of multiple diseases in the same patient
  • Convenient subcutaneous injection
Next Generation Vaccines What’s New

Etubics is developing innovative immunotherapies and vaccines, utilizing our proprietary gene delivery platform and our patented human E.C7 human cell line, together the Etubics Platform.

The Etubics Platform provides the following capabilities: a long lasting “active” immune response against diseases and induces both cell mediated immunity and antibody.

Find out more about our Technology

Advances in Global Health through Sensing Technologies 2015- Etubics CEO Frank Jones will present on April 20, 2015 at the SPIE conference entitled “Advances in Global Health through Sensing Technologies 2015” being held at the Baltimore Convention Center, Baltimore, Maryland, United States. 20 – 24 April 2015

World Vaccine Congress 2015- Etubics CEO Frank Jones will present at the World Vaccine Congress being held  April 7-9, 2015 at the Walter E. Washington Convention Center in Washington D.C.  Dr. Jones will present on April 8, 2015 at 3:10pm.

vaccine2

Last Updated: April 2015